Article Text
Statistics from Altmetric.com
QUESTION: In patients with depression, does initial treatment with fluoxetine improve clinical, quality of life, and economic outcomes better than desipramine or imipramine?
Design
Randomised (allocation concealed*), unblinded,* controlled trial with 24 month follow up.
Setting
Primary care clinics in a health maintenance organisation in Seattle, Washington, USA.
Patients
536 patients (median age 41 y, 72% women) who were beginning antidepressant drug treatment. Exclusion criteria were use of antidepressant drugs in the previous 90 days, alcohol abuse, psychotic symptoms, history of mania, recent use of lithium or antipsychotics, or contraindication to the study drug. Follow up was 81% at 12 months and 72% at 24 months.
Intervention
Patients were allocated to {fluoxetine (n=173), desipramine (n=181), or imipramine (n=182)}†.
Main outcome measures.
Continuing use of initial medication; remission of depression; change in Hamilton Depression Rating Scale …
Footnotes
-
Source of funding: Lilly Research Laboratories.
-
For correspondence: Dr G E Simon, Center for Health Studies, Group Health Cooperative, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101-1448, USA. Fax +1 206 287 2871.
-
A modified version of the abstract and commentary also appears in Evidence- Based Mental Health.
↵† Simon GE, VonKorff M, Heiligenstein JH, et al. JAMA. 1996;275:1897–902.